Sterling Capital Management
OVID icon

Sterling Capital Management’s Ovid Therapeutics OVID Stock Holding History

Sterling Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.54K Buy
3,428
+642
+23% +$1.68K ﹤0.01% 2598
2026
Q2 		$7.49K Buy
+2,786
New +$7.19K ﹤0.01% 2385
2025
Q2 		– Sell
-61
Closed -$19 – 3358
2025
Q1 		$19 Hold
61
– – ﹤0.01% 3200
2024
Q4 		$57 Hold
61
– – ﹤0.01% 3207
2024
Q3 		$72 Buy
+61
New +$64 ﹤0.01% 3218

Other funds holding OVID

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Sterling Capital Management's OVID Position: Q3 2026 in Review

Sterling Capital Management increased its Ovid Therapeutics (OVID) stake by 23% in Q3 2026, buying an estimated $1.68K and bringing the position to 3,428 shares worth $8.54K. The position accounts for ﹤0.01% of the portfolio, ranked #2598.

Sterling Capital Management first reported a position in OVID in Q3 2024 and has held it in 5 quarters since. 33 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • Sterling Capital Management held 3,428 shares of Ovid Therapeutics worth $8.54K as of Q3 2026.
  • Sterling Capital Management bought 642 Ovid Therapeutics shares in Q3 2026, an estimated $1.68K.
  • Ovid Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2598 holding.
  • Sterling Capital Management first reported a position in Ovid Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 33 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.